GSK widens the market for Zejula as FDA signs off on the PARP inhibitor for use in ovarian cancer patients without BRCA mutations

GSK has vastly expanded its market for cancer therapy Zejula — the crown jewel at the heart of its $5 billion acquisition of Tesaro — by winning FDA approval for the drug in a large subset of patients with ovarian cancer.